Toward elimination of perinatal human immunodeficiency virus transmission in the United States: effectiveness of funded prevention programs, 1999-2001

American Journal of Obstetrics and Gynecology

Volumn 197, Issue 3 SUPPL., 2007, Pages

  Sansom, Stephanie L ^a   Harris, Norma S ^a   Sadek, Ramses ^a   Lampe, Margaret A ^a   Ruffo, Nan M ^a,b   Fowler, Mary Glenn ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

antiretroviral; perinatal HIV; prevention; surveillance

Indexed keywords

ANTIRETROVIRUS AGENT;

CONTROLLED STUDY; DEMOGRAPHY; FUNDING; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MOTHER FETUS RELATIONSHIP; PERINATAL PERIOD; PRENATAL CARE; PRIORITY JOURNAL; REVIEW; UNITED STATES; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); DISEASE TRANSMISSION, VERTICAL; FEMALE; FINANCING, GOVERNMENT; GOALS; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT, NEWBORN; POPULATION SURVEILLANCE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRIMARY PREVENTION; UNITED STATES;

EID: 34548511533     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.03.005     Document Type: Review

References (23)

1. CDC. Reduction in perinatal transmission of human immunodeficiency virus-United States, 1985-2006. MMWR Morbid Mortal Wkly Rep 21 (2006) 592-597
2. Connor E.M., Sperling R.S., Gelber R., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 331 (1994) 1173-1180
3. Cooper E.R., Charurat M., Mofenson L., et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29 (2002) 484-494
4. U.S. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (2005). http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guideli nes&Search=Off&GuidelineID=9&ClassID=2 Nov 17. Available at: http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guideli nes&Search=Off&GuidelineID=9&ClassID=2. Accessed March 31, 2006.
5. Wade N.A., Birkhead G.S., Warren B.L., et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 339 (1998) 1409-1414
6. Guay L.A., Musoke P., Hom D.L., et al. Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS 16 (2002) 1391-1400
7. PETRA Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 359 (2002) 1178-1186
8. Moodley D., Moodley J., Coovadia H., et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 187 (2002) 725-735
9. Davis S., Byers R., Lindegren M.L., Caldwell M.B., Karon J.M., and Gwinn M. Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA 274 (1995) 952-955
10. Centers for Disease Control and Prevention. Characteristics of persons living with AIDS at the end of 1997. HIV/AIDS Surveillance Supplemental Report 1990;5:1-14. Available at: http://www.cdc.gov/hiv/stats/hasrsupp51.pdf. Accessed March 31, 2006. 11. Centers for Disease Control and Prevention. HIV prevention strategic plan through 2005. 2001; Atlanta, GA: Author. Available at: http://www.cdc.gov/hiv/partners/psp.htm. Accessed March 31, 2006.
11. Centers for Disease Control and Prevention. HIV preventtion strategic plan through 2005 (2001), Author, Atlanta, GA. http://www.cdc.gov/hiv/partners/psp/htm Avilable at: http://www.cdc.gov/hiv/partners/psp/htm. accessed March 31, 2006.
12. Holtgrave D.R., Gilliam A., Gentry D., and Sy F.S. Evaluating HIV prevention efforts to reduce new infections and ensure accountability. AIDS Educ Prev 14 Suppl A (2002) 1-4
13. Rugg D., Buehler J., Renaud M., et al. Evaluating HIV prevention: a framework for national, state and local levels. Am J Eval 20 (1999) 35-56
14. Centers for Disease Control and Prevention. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 48 RR-13 (1999) 1-28. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4813a1.htm Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4813a1.htm. Accessed March 31, 2006.
15. In: Holtgrave D.R. (Ed). Handbook of economic evaluation of HIV prevention programs (1998), Plenum, New York (NY)
16. Sansom S., Anderson J., Farnham P.G., Dominguez K., Soorapanth S., and Clark J. Updated estimates of health care utilization and costs among perinatally HIV-infected children. J Acquir Immune Defic Syndr 41 (2006) 521-526
17. Sansom S., Anderson J., Dominguez K., Earp M.J., and Farnham P. Updated quality adjusted life year estimates for perinatally HIV-infected children. Presented at the 27th Annual Meeting of the Society for Medical Decisonmaking, Oct 24, San Francisco, CA. (2005)
18. Tengs T.O., Adams M.E., Pliskin J.S., et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 15 (1995) 369-390
19. Martin J., Hamilton B., Ventura S., Menacher F., Park M.M., and Sutton P.D. Births: final data for 2001. Natl Vital Stat Rep 51 (2002). http://www.cdc.gov/nchs/data/nvsr/nvsr51/nvsr51_02.pdf Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr51/nvsr51_02.pdf. Accessed March 31, 2006.
20. Garcia P., Kalish L., Pitt J., et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 341 (1999) 394-402
21. Welles S., Pitt J., Colgrave R., et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infant Study Transmission Group. AIDS 14 (2000) 263-271
22. Dunn D.T., Newell M.L., Ades A.E., and Peckham C.S. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 340 (1992) 585-588
23. The International Perinatal HIV Group. The mode of delivery and risk of vertical transmission of human immunodeficiency virus type-1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 340 (1999) 977-987